Patents by Inventor Matthew John Traylor

Matthew John Traylor has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12331334
    Abstract: Provided are nucleic acid molecules, including vectors and plasmids, encoding modified u-PA polypeptides and fusion proteins containing the modified u-PA polypeptides. The u-PA polypeptides are modified to have altered activity and/or specificity so that they cleave a complement protein, such as complement protein C3, to thereby inhibit complement activation. The nucleic acids and encoded modified u-PA polypeptides and fusion proteins that inhibit complement activation can be used for treatment of diseases and conditions that are mediated by complement activation, or in which complement activation plays a role. These disorders include ischemic and reperfusion disorders, including myocardial infarction and stroke, sepsis, autoimmune diseases, diabetic retinopathies, age-related macular degeneration, transplanted organ rejection, inflammatory diseases and diseases with an inflammatory component.
    Type: Grant
    Filed: February 10, 2023
    Date of Patent: June 17, 2025
    Assignee: Vertex Pharmaceuticals, Incorporated
    Inventors: Edwin L. Madison, Christopher Thanos, Vanessa Soros, Mikhail Popkov, Kimberly Tipton, Matthew John Traylor, Eric Steven Furfine, Jeffrey Charles Way
  • Publication number: 20250136965
    Abstract: Provided herein are Complement Factor I (CFI) variants that exhibit at least one improved characteristic relative to a wild type CFI. CFI variants of the disclosure can exhibit tunable specificity and activity. Also included are CFI-containing fusion constructs comprising at least one domain of CFI, for example, wild type full length CFI fused to human serum albumin. Also included are methods of making and using such CFI variants and fusion constructs. The CFI variants and fusion constructs provided herein may be useful for treating a disease or condition associated with dysregulation of the complement system or a deficiency of CFI.
    Type: Application
    Filed: September 9, 2024
    Publication date: May 1, 2025
    Inventors: Grant E. BLOUSE, Brajesh KUMAR, Tom KNUDSEN, Jan Kristian JENSEN, Emil OLDENBURG, Christine René SCHAR, Matthew John TRAYLOR, Eric Steven FURFINE, Jeffrey Charles WAY, Agnieszka JENDROSZEK, Arzu SANDIKCI, Jim MCGUIRE, Shyam Rajan IYER, Natacha LE MOAN
  • Patent number: 12116606
    Abstract: Provided herein are Complement Factor I (CFI) variants that exhibit at least one improved characteristic relative to a wild type CFI. CFI variants of the disclosure can exhibit tunable specificity and activity. Also included are CFI-containing fusion constructs comprising at least one domain of CFI, for example, wild type full length CFI fused to human serum albumin. Also included are methods of making and using such CFI variants and fusion constructs. The CFI variants and fusion constructs provided herein may be useful for treating a disease or condition associated with dysregulation of the complement system or a deficiency of CFI.
    Type: Grant
    Filed: June 14, 2021
    Date of Patent: October 15, 2024
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Grant E. Blouse, Brajesh Kumar, Tom Knudsen, Jan Kristian Jensen, Emil Oldenburg, Christine René Schar, Matthew John Traylor, Eric Steven Furfine, Jeffrey Charles Way, Agnieszka Jendroszek, Arzu Sandikci, Jim McGuire, Shyam Rajan Iyer, Natacha Le Moan
  • Publication number: 20230242895
    Abstract: Provided are nucleic acid molecules, including vectors and plasmids, encoding modified u-PA polypeptides and fusion proteins containing the modified u-PA polypeptides. The u-PA polypeptides are modified to have altered activity and/or specificity so that they cleave a complement protein, such as complement protein C3, to thereby inhibit complement activation. The nucleic acids and encoded modified u-PA polypeptides and fusion proteins that inhibit complement activation can be used for treatment of diseases and conditions that are mediated by complement activation, or in which complement activation plays a role. These disorders include ischemic and reperfusion disorders, including myocardial infarction and stroke, sepsis, autoimmune diseases, diabetic retinopathies, age-related macular degeneration, transplanted organ rejection, inflammatory diseases and diseases with an inflammatory component.
    Type: Application
    Filed: February 10, 2023
    Publication date: August 3, 2023
    Inventors: Edwin L. MADISON, Christopher Thanos, Vanessa Soros, Mikhail Popkov, Kimberly Tipton, Matthew John Traylor, Eric Steven Furfine, Jeffrey Charles Way
  • Patent number: 11613744
    Abstract: Provided are u-PA polypeptides and fusion proteins containing the u-PA polypeptides. The u-PA polypeptides are modified to have altered activity and/or specificity so that they cleave a complement protein, such as complement protein C3, to thereby inhibit complement activation. The modified u-PA polypeptides and fusion proteins that inhibit complement activation can be used for treatment of diseases and conditions that are mediated by complement activation, or in which complement activation plays a role. These disorders include ischemic and reperfusion disorders, including myocardial infarction and stroke, sepsis, autoimmune diseases, diabetic retinopathies, age-related macular degeneration, transplanted organ rejection, inflammatory diseases and diseases with an inflammatory component.
    Type: Grant
    Filed: January 3, 2020
    Date of Patent: March 28, 2023
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Edwin L. Madison, Christopher Thanos, Vanessa Soros, Mikhail Popkov, Kimberly Tipton, Matthew John Traylor, Eric Steven Furfine, Jeffrey Charles Way
  • Publication number: 20230038638
    Abstract: Provided herein are Complement Factor I (CFI) variants that exhibit at least one improved characteristic relative to a wild type CFI. CFI variants of the disclosure can exhibit tunable specificity and activity. Also included are CFI-containing fusion constructs comprising at least one domain of CFI, for example, wild type full length CFI fused to human serum albumin. Also included are methods of making and using such CFI variants and fusion constructs. The CFI variants and fusion constructs provided herein may be useful for treating a disease or condition associated with dysregulation of the complement system or a deficiency of CFI.
    Type: Application
    Filed: June 14, 2021
    Publication date: February 9, 2023
    Inventors: Grant E. BLOUSE, Brajesh KUMAR, Tom KNUDSEN, Jan Kristian JENSEN, Emil OLDENBURG, Christine René SCHAR, Matthew John TRAYLOR, Eric Steven FURFINE, Jeffrey Charles WAY, Agnieszka JENDROSZEK, Arzu SANDIKCI, Jim MCGUIRE, Shyam Rajan IYER, Natacha LE MOAN
  • Publication number: 20210222143
    Abstract: Provided are u-PA polypeptides and fusion proteins containing the u-PA polypeptides. The u-PA polypeptides are modified to have altered activity and/or specificity so that they cleave a complement protein, such as complement protein C3, to thereby inhibit complement activation. The modified u-PA polypeptides and fusion proteins that inhibit complement activation can be used for treatment of diseases and conditions that are mediated by complement activation, or in which complement activation plays a role. These disorders include ischemic and reperfusion disorders, including myocardial infarction and stroke, sepsis, autoimmune diseases, diabetic retinopathies, age-related macular degeneration, transplanted organ rejection, inflammatory diseases and diseases with an inflammatory component.
    Type: Application
    Filed: January 3, 2020
    Publication date: July 22, 2021
    Inventors: Edwin L. Madison, Christopher Thanos, Vanessa Soros, Mikhail Popkov, Kimberly Tipton, Matthew John Traylor, Eric Steven Furfine, Jeffrey Charles Way
  • Publication number: 20200208133
    Abstract: Provided are u-PA polypeptides and fusion proteins containing the u-PA polypeptides. The u-PA polypeptides are modified to have altered activity and/or specificity so that they cleave a complement protein, such as complement protein C3, to thereby inhibit complement activation. The modified u-PA polypeptides and fusion proteins that inhibit complement activation can be used for treatment of diseases and conditions that are mediated by complement activation, or in which complement activation plays a role. These disorders include ischemic and reperfusion disorders, including myocardial infarction and stroke, sepsis, autoimmune diseases, diabetic retinopathies, age-related macular degeneration, transplanted organ rejection, inflammatory diseases and diseases with an inflammatory component.
    Type: Application
    Filed: January 3, 2020
    Publication date: July 2, 2020
    Inventors: Edwin L. Madison, Christopher Thanos, Vanessa Soros, Mikhail Popkov, Kimberly Tipton, Matthew John Traylor, Eric Steven Furfine, Jeffrey Charles Way